Director Of Bio-Techne Trades $4.80 Million In Company Stock
Randolph C Steer, Director at Bio-Techne (NASDAQ:TECH), made a large buy and sell of company shares on September 7, according to a new SEC filing.
CFO Of Bio-Techne Trades $6.14 Million In Company Stock
James Hippel, Chief Financial Officer at Bio-Techne (NASDAQ:TECH), made a large buy and sell of company shares on September 2, according to a new SEC filing.
Bio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis
Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
Bio-Techne Set To Join S&P 500; To Replace Maxim Integrated Products
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210824-1442797/1442797_5mxim6uscr6syke.pdf
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year.
Recap: Bio-Techne Q4 Earnings
Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share were up 87.00% over the past year to $1.87, which beat the estimate of $1.70.
Bio-Techne Q4 Adj. EPS $1.87 Beats $1.70 Estimate, Sales $259.03M Beat $244.62M Estimate
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.70 by 10 percent. This is a 87 percent increase over earnings of $1.00 per share from the same